Management of hypersplenism in hemolytic anemias
Pediatric Hematology Oncology Journal · 2024-12 · 9 (4) · 223-227
DOI: 10.1016/j.phoj.2024.07.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Hematology Oncology Journal, 2024-12. Verfasst von Amita Mahajan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The clinical course of patients with chronic hemolytic anemia can be complicated by the development of splenomegaly and consequent hypersplenism. This may warrant management by medical or surgical methods. Furthermore, in some patients, splenic manipulation may be warranted in the absence of hypersplenism, spleen being the primary site of red cell destruction. Wherever possible, splenectomy is avoided or deferred in view of the life-long risks of infection and thrombosis associated with this procedure. Optimal management in hemolytic anemia, therefore, incorporates prevention of hypersplenism as one of the key treatment goals.
Zitieren
APA
Mahajan, A. (2024). Management of hypersplenism in hemolytic anemias. Pediatric Hematology Oncology Journal, 9(4), 223-227. https://doi.org/10.1016/j.phoj.2024.07.004
Vancouver
Mahajan A. Management of hypersplenism in hemolytic anemias. Pediatric Hematology Oncology Journal. 2024;9(4):223-227. doi:10.1016/j.phoj.2024.07.004
BibTeX
@article{Mahajan2024,
author = {Mahajan, Amita},
title = {Management of hypersplenism in hemolytic anemias},
journal = {Pediatric Hematology Oncology Journal},
year = {2024},
volume = {9},
number = {4},
pages = {223--227},
doi = {10.1016/j.phoj.2024.07.004}
}
EUVIMED